We are live on ! Find out more
ASLN

ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN

Delisted

ASLN was delisted on the 18th of July, 2024.

Back to rankings

31 hedge funds and large institutions have $88.2M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

1% less capital invested

Capital invested by funds: $88.7M → $88.2M (-$506K)

24% less funds holding

Funds holding: 41 → 31 (-10)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
31
Holders Change
-10
Holders Change %
-24.39%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
13
Reduced
7
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$7.02M
2
PIM
Platinum Investment Management
Australia
+$1.16M
3
MP
Mangrove Partners
Connecticut
+$1.05M
4
Morgan Stanley
Morgan Stanley
New York
+$586K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$356K

Top Sellers

Rank Fund Capital Flow
1
LM
Luminus Management
Texas
-$5.88M
2
MIM
Monashee Investment Management
Massachusetts
-$1.41M
3
LGM
Logos Global Management
California
-$938K
4
AAA
Affinity Asset Advisors
New York
-$670K
5
CCM
CAAS Capital Management
New York
-$503K

ASLN Hedge Fund Activity: Q2 2021 in Review

31 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q2 2021, worth a combined $88.2M — down 0.57% from $88.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ASLN and 1 opened new positions — a net loss of 10 holders — while 7 trimmed existing stakes and 13 added.

The largest buyer was Citadel Advisors, adding an estimated $7.02M. The largest seller was Luminus Management, exiting entirely with an estimated $5.88M sold.

  • 31 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q2 2021, down from 41 in Q1 2021.
  • Funds reported $88.2M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q2 2021, down 0.57% quarter-over-quarter.
  • 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q2 2021 and 11 closed out, a net change of -10 holders.
  • The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q2 2021 was Citadel Advisors, an estimated $7.02M added.
  • The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q2 2021 was Luminus Management, an estimated $5.88M sold.

Based on aggregated 13F filings for Q2 2021.